- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
短期的强势行情可能结束，投资者及时短线卖出、离场观望为宜。
- 中期趋势：
-
- 长期趋势：
已有380家主力机构披露2024-12-31报告期持股数据，持仓量总计3.38亿股，占流通A股57.76%
- 波段诊断：
-
技术面诊股
诊断结果：3.6技术面打败了66%的股票
技术面评分前10的股票
近期的平均成本为36.25元。
平均成本
近期的平均成本为36.25元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"36.25","date":1743493885,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势跑赢大盘，接近行业平均水平。
[{"date":"2025.04.02","stock":"-0.63","trade":"0.10","ind":"0.09"},{"date":"2025.04.01","stock":"2.65","trade":"4.61","ind":"-0.01"},{"date":"2025.03.31","stock":"-1.55","trade":"-1.52","ind":"-0.97"},{"date":"2025.03.28","stock":"1.69","trade":"-0.35","ind":"-0.57"},{"date":"2025.03.27","stock":"1.00","trade":"2.25","ind":"0.23"},{"date":"2025.03.26","stock":"-0.96","trade":"0.93","ind":"-0.05"},{"date":"2025.03.25","stock":"1.23","trade":"0.61","ind":"-0.43"},{"date":"2025.03.24","stock":"0.40","trade":"-1.49","ind":"0.07"},{"date":"2025.03.21","stock":"0.26","trade":"-1.36","ind":"-1.76"},{"date":"2025.03.20","stock":"-0.69","trade":"-0.68","ind":"-0.91"},{"date":"2025.03.19","stock":"0.09","trade":"-0.21","ind":"-0.32"},{"date":"2025.03.18","stock":"0.11","trade":"0.53","ind":"0.52"},{"date":"2025.03.17","stock":"-0.48","trade":"0.25","ind":"-0.19"},{"date":"2025.03.14","stock":"1.42","trade":"2.51","ind":"2.26"},{"date":"2025.03.13","stock":"0.52","trade":"-0.67","ind":"-0.99"},{"date":"2025.03.12","stock":"-0.38","trade":"-0.35","ind":"-0.17"},{"date":"2025.03.11","stock":"0.26","trade":"0.05","ind":"0.33"},{"date":"2025.03.10","stock":"1.03","trade":"1.54","ind":"-0.17"},{"date":"2025.03.07","stock":"-0.84","trade":"-0.69","ind":"-0.50"},{"date":"2025.03.06","stock":"0.23","trade":"1.14","ind":"1.77"},{"date":"2025.03.05","stock":"-0.46","trade":"-0.48","ind":"0.28"}]
丽珠集团,深证成指,化学制药指数
压力支撑
该股压力位为36.23元，支撑位为35.99元。
[{"text":"\u538b\u529b\u4f4d","value":"36.23","date":1743523200,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"35.99","date":1743523200,"color":"0x0b52a1"}]
多空趋势
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：5.9资金面打败了95%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金流入较多，投资者可加强关注该行业的个股。
更新时间：04月02日 20:30
| 机构今日流向(万元) | -1112.27 | 机构5日流向(万元) | 5522.67 |
| 机构10日流向(万元) | 1167.65 | 机构20日流向(万元) | -923.83 |
机构持仓
2024-12-31 与 2024-06-30 相比，主力机构持仓量减少2802.74万股，其中基金净减仓14家，主力净减仓102家，请投资者中长期谨慎为宜。
截止2024-12-31，共380家主力机构（基金372家，保险公司1家，一般法人4家，QFII2家，社保基金1家），持仓量总计33752.91万股，占流通A股57.76%
其中，基金持仓与2024-06-30相比：
增仓：92家 ，增持 558.46万股
减仓：106家 ，减持 360.85万股
新出现在主力名单中：148家 ，持有2796.08万股
从主力名单中消失：250家 ，原持有4475.86万股
其中，基金持仓与2024-06-30相比：
增仓：92家 ，增持 558.46万股
减仓：106家 ，减持 360.85万股
新出现在主力名单中：148家 ，持有2796.08万股
从主力名单中消失：250家 ，原持有4475.86万股
消息面诊股
诊断结果：6消息面打败了75%的股票
今日有利好新闻的公司
近期该股消息面总体多空平衡，没有较强的利好或利空趋势。
更多>>个股资讯
- 丽珠集团：4月1日获融资买入2126.72万元，占
2025-04-02 - 丽珠集团副总裁杨亮辞职
2025-04-01 - 丽珠集团累计回购1.03%股份 耗资3.42亿元
2025-04-01 - 同一天！两大龙头械企，副总裁辞职
2025-04-01 - 丽珠集团：3月31日获融资买入1514.44万元
2025-04-01 - 一季度净利润预增138%+极端放量，减肥药龙头受关
2025-04-01 - 糖尿病“药王”易主，明星药首破20亿！扬子江、甘李
2025-03-31 - 丽珠集团拟增资10亿为亏损子公司输血，PD-1项目
2025-03-31 - 丽珠集团获87家机构调研：目前P-CAB产品片剂预
2025-03-31 - 丽珠集团：杨亮辞任公司副总裁职务
2025-03-31
消息列表
| 一般消息 | 高管变动 | 因个人发展原因 | 2025-03-31 |
| 一般消息 | 重大事项 | 关联交易 | 2025-03-31 |
| 利好 | 分红转增 | 10派11元(含税) | 2025-03-27 |
| 一般消息 | 募资投向 | 公司购买资产 | 2025-03-27 |
| 一般消息 | 重大事项 | 关联交易 | 2025-01-02 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2024-12-31 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2024-12-31 |
| 一般消息 | 股东大会 | 临时股东大会 | 2024-11-29 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2024-10-14 |
| 一般消息 | 分红转增 | 不分配不转增 | 2024-08-23 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 2条 | 0条 | 2条 |
| 利空 | 0条 | 0条 | 0条 |
行业面诊股
诊断结果：7.5行业面打败了98%的股票
化学制药行业最新资金流向
近10日来该行业走势不明显，跑赢大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势不明显，跑赢大盘。
[{"date":"2025.04.02","price":"0.09","value":"0.10"},{"date":"2025.04.01","price":"-0.01","value":"4.61"},{"date":"2025.03.31","price":"-0.97","value":"-1.52"},{"date":"2025.03.28","price":"-0.57","value":"-0.35"},{"date":"2025.03.27","price":"0.23","value":"2.25"},{"date":"2025.03.26","price":"-0.05","value":"0.93"},{"date":"2025.03.25","price":"-0.43","value":"0.61"},{"date":"2025.03.24","price":"0.07","value":"-1.49"},{"date":"2025.03.21","price":"-1.76","value":"-1.36"},{"date":"2025.03.20","price":"-0.91","value":"-0.68"},{"date":"2025.03.19","price":"-0.32","value":"-0.21"},{"date":"2025.03.18","price":"0.52","value":"0.53"},{"date":"2025.03.17","price":"-0.19","value":"0.25"},{"date":"2025.03.14","price":"2.26","value":"2.51"},{"date":"2025.03.13","price":"-0.99","value":"-0.67"},{"date":"2025.03.12","price":"-0.17","value":"-0.35"},{"date":"2025.03.11","price":"0.33","value":"0.05"},{"date":"2025.03.10","price":"-0.17","value":"1.54"},{"date":"2025.03.07","price":"-0.50","value":"-0.69"},{"date":"2025.03.06","price":"1.77","value":"1.14"},{"date":"2025.03.05","price":"0.28","value":"-0.48"}]
深证成指,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 九典制药 | 488.68% | 5.64% | 4.8分 |
| 2 | 海翔药业 | 217.07% | -0.38% | 5.5分 |
| 3 | 金陵药业 | 155.85% | -0.59% | 5.2分 |
| 4 | 润都股份 | 82.92% | 35.83% | 5.1分 |
| 5 | 金城医药 | 62.08% | 1.49% | 5.3分 |
| 6 | 多瑞医药 | 52.82% | 34.75% | 4.8分 |
| 8 | 圣诺生物 | 33.90% | 25.85% | 6.0分 |
| 10 | 泽璟制药 | 26.05% | 21.52% | 5.6分 |
| 12 | 海思科 | 22.69% | 12.02% | 6.1分 |
| 14 | 科伦药业 | 18.44% | 20.92% | 6.0分 |
| 16 | 博瑞医药 | 17.40% | 5.41% | 4.3分 |
| 18 | 健友股份 | 15.94% | 2.21% | 4.7分 |
| 20 | 京新药业 | 13.73% | 3.53% | 5.3分 |
| 22 | 美诺华 | 13.49% | 6.62% | 5.0分 |
| 24 | 迪哲医药 | 13.17% | 15.94% | 5.5分 |
| 26 | 华特达因 | 12.67% | 0.07% | 4.7分 |
| 28 | 罗欣药业 | 11.70% | 3.08% | 4.5分 |
| 30 | 海创药业 | 10.83% | 27.11% | 5.3分 |
| 32 | *ST景峰 | 10.34% | -2.61% | 4.7分 |
| 34 | 千红制药 | 9.86% | 5.69% | 5.9分 |
| 36 | 联环药业 | 9.57% | 2.56% | 5.0分 |
| 38 | 华海药业 | 9.14% | 2.51% | 5.6分 |
| 40 | 国邦医药 | 8.88% | 2.38% | 4.7分 |
| 42 | 卫信康 | 8.13% | 1.99% | 4.0分 |
| 44 | 东北制药 | 7.79% | 2.33% | 5.2分 |
| 46 | 小方制药 | 7.74% | 7.54% | 4.7分 |
| 48 | 海欣股份 | 7.52% | 9.41% | 4.5分 |
| 50 | 誉衡药业 | 7.38% | 6.07% | 5.2分 |
| 52 | 仟源医药 | 7.18% | 7.89% | 5.6分 |
| 54 | 盟科药业 | 6.07% | 5.52% | 4.5分 |
| 56 | 福元医药 | 6.04% | 1.91% | 4.9分 |
| 58 | 百济神州 | 5.86% | 14.05% | 5.5分 |
| 60 | 宣泰医药 | 5.70% | 5.60% | 5.0分 |
| 62 | 山河药辅 | 5.66% | 1.51% | 4.6分 |
| 64 | 华邦健康 | 5.47% | 0.00% | 5.0分 |
| 66 | 丽珠集团 | 5.39% | 3.13% | 5.5分 |
| 68 | 恩华药业 | 5.05% | -0.35% | 5.1分 |
| 70 | 同和药业 | 4.84% | 0.88% | 4.9分 |
| 72 | 康芝药业 | 4.70% | 0.20% | 4.3分 |
| 74 | 立方制药 | 4.28% | 1.67% | 5.5分 |
| 76 | 键凯科技 | 3.71% | 9.82% | 3.8分 |
| 78 | 神奇制药 | 3.20% | -0.31% | 4.5分 |
| 80 | 海普瑞 | 3.12% | 3.49% | 5.3分 |
| 82 | 泰恩康 | 2.85% | 2.23% | 4.6分 |
| 84 | 复星医药 | 2.70% | 3.71% | 5.3分 |
| 86 | 东诚药业 | 2.57% | 1.49% | 5.4分 |
| 88 | 德展健康 | 2.44% | -2.61% | 3.8分 |
| 90 | 华润双鹤 | 2.37% | 3.03% | 5.1分 |
| 92 | 汉商集团 | 2.08% | 4.10% | 4.4分 |
| 94 | 广济药业 | 1.99% | -1.75% | 4.2分 |
| 96 | 复旦张江 | 1.85% | 3.12% | 4.0分 |
| 98 | 新和成 | 1.47% | 0.64% | 5.5分 |
| 100 | 昂利康 | 0.92% | 0.92% | 5.3分 |
| 102 | 赛分科技 | 0.88% | 0.18% | 4.7分 |
| 104 | 民生健康 | 0.75% | 1.52% | 4.2分 |
| 106 | 海森药业 | 0.28% | 3.78% | 4.4分 |
| 108 | 共同药业 | 0.00% | 1.99% | 3.5分 |
| 110 | 宏源药业 | -0.07% | 0.93% | 4.3分 |
| 112 | 威尔药业 | -0.88% | -0.69% | 4.6分 |
| 114 | 金石亚药 | -1.16% | 1.31% | 4.0分 |
| 116 | 华纳药厂 | -1.37% | 1.25% | 5.2分 |
| 118 | ST三圣 | -1.85% | -1.59% | 4.1分 |
| 120 | 向日葵 | -2.57% | -0.33% | 3.6分 |
| 122 | 东亚药业 | -3.01% | -8.16% | 3.4分 |
| 124 | 科源制药 | -5.09% | 3.45% | 3.8分 |
| 126 | 赛托生物 | -7.24% | -0.52% | 4.1分 |
| 128 | 灵康药业 | -8.23% | -0.67% | 3.7分 |
| 130 | 普洛药业 | -11.87% | -0.26% | 5.1分 |
| 132 | 江苏吴中 | -16.72% | -2.89% | 4.2分 |
| 134 | - | -23.69% | 0.00% | 分 |
| 136 | 川宁生物 | - | 3.72% | 5.7分 |
| 138 | 亨迪药业 | - | 5.61% | 3.3分 |
| 140 | 本立科技 | - | 3.34% | 4.1分 |
| 142 | 天宇股份 | - | 1.20% | 4.6分 |
| 144 | 富祥药业 | - | 6.97% | 4.4分 |
| 146 | 尔康制药 | - | -1.87% | 4.3分 |
| 148 | 莱美药业 | - | -5.38% | 4.0分 |
| 150 | 信立泰 | - | 9.94% | 6.3分 |
| 152 | 双鹭药业 | - | -1.44% | 3.7分 |
| 154 | 新华制药 | - | 1.06% | 5.1分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2024-12-31 ]公司经营
盈利能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 6/228 ， 10/228。
[{"date":"2024-12-31","value":"14.77","vol":"10.55"},{"date":"2024-09-30","value":"11.86","vol":"4.52"},{"date":"2024-06-30","value":"8.38","vol":"3.49"},{"date":"2024-03-31","value":"4.24","vol":"2.32"},{"date":"2023-12-31","value":"14.00","vol":"-2.41"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
14.77 | 11.86 | 8.38 | 4.24 | 14.00 |
| 行业(%) | 10.55 | 4.52 | 3.49 | 2.32 | -2.41 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"65.45","vol":"53.60"},{"date":"2024-09-30","value":"65.81","vol":"50.55"},{"date":"2024-06-30","value":"65.96","vol":"50.91"},{"date":"2024-03-31","value":"64.67","vol":"50.62"},{"date":"2023-12-31","value":"64.08","vol":"51.63"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
65.45 | 65.81 | 65.96 | 64.67 | 64.08 |
| 行业(%) | 53.60 | 50.55 | 50.91 | 50.62 | 51.63 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：偏弱，与行业平均有较大差距，两项指标的行业排名分别为 21/228 ， 17/228。
[{"date":"2024-12-31","value":"-4.97","vol":"31.52"},{"date":"2024-09-30","value":"-5.94","vol":"44.93"},{"date":"2024-06-30","value":"-6.09","vol":"700.68"},{"date":"2024-03-31","value":"-4.99","vol":"749.72"},{"date":"2023-12-31","value":"-1.58","vol":"353.65"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
-4.97 | -5.94 | -6.09 | -4.99 | -1.58 |
| 行业(%) | 31.52 | 44.93 | 700.68 | 749.72 | 353.65 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"5.50","vol":"102.80"},{"date":"2024-09-30","value":"4.44","vol":"-16.98"},{"date":"2024-06-30","value":"3.21","vol":"7.37"},{"date":"2024-03-31","value":"4.45","vol":"18.10"},{"date":"2023-12-31","value":"2.32","vol":"-47.20"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
5.50 | 4.44 | 3.21 | 4.45 | 2.32 |
| 行业(%) | 102.80 | -16.98 | 7.37 | 18.10 | -47.20 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 16/228 ， 23/228。
[{"date":"2024-12-31","value":"0.48","vol":"0.52"},{"date":"2024-09-30","value":"0.36","vol":"0.33"},{"date":"2024-06-30","value":"0.25","vol":"0.23"},{"date":"2024-03-31","value":"0.13","vol":"0.12"},{"date":"2023-12-31","value":"0.50","vol":"0.44"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.48 | 0.36 | 0.25 | 0.13 | 0.50 |
| 行业(次) | 0.52 | 0.33 | 0.23 | 0.12 | 0.44 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"2.01","vol":"3.10"},{"date":"2024-09-30","value":"1.53","vol":"2.16"},{"date":"2024-06-30","value":"1.06","vol":"1.50"},{"date":"2024-03-31","value":"0.56","vol":"0.74"},{"date":"2023-12-31","value":"2.18","vol":"2.78"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
2.01 | 1.53 | 1.06 | 0.56 | 2.18 |
| 行业(次) | 3.10 | 2.16 | 1.50 | 0.74 | 2.78 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 10/228 ， 15/228。
[{"date":"2024-12-31","value":"24.57","vol":"-10.59"},{"date":"2024-09-30","value":"27.79","vol":"-10.05"},{"date":"2024-06-30","value":"19.93","vol":"-254.27"},{"date":"2024-03-31","value":"28.50","vol":"-4.44"},{"date":"2023-12-31","value":"37.35","vol":"-123.06"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 24.57 | 27.79 | 19.93 | 28.50 | 37.35 |
| 行业 | -10.59 | -10.05 | -254.27 | -4.44 | -123.06 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"0.91","vol":"1.31"},{"date":"2024-09-30","value":"","vol":"0.00"},{"date":"2024-06-30","value":"0.80","vol":"2.18"},{"date":"2024-03-31","value":"","vol":"0.00"},{"date":"2023-12-31","value":"0.92","vol":"2.34"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | 0.91 | - | 0.80 | - | 0.92 |
| 行业 | 1.31 | 0.00 | 2.18 | 0.00 | 2.34 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 5/228 ， 19/228。
[{"date":"2024-12-31","value":"2.15","vol":"3.20"},{"date":"2024-09-30","value":"1.84","vol":"3.65"},{"date":"2024-06-30","value":"1.81","vol":"3.58"},{"date":"2024-03-31","value":"2.06","vol":"3.74"},{"date":"2023-12-31","value":"2.13","vol":"3.71"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 流动比率 |
2.15 | 1.84 | 1.81 | 2.06 | 2.13 |
| 行业 | 3.20 | 3.65 | 3.58 | 3.74 | 3.71 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"1.86","vol":"2.59"},{"date":"2024-09-30","value":"1.58","vol":"2.91"},{"date":"2024-06-30","value":"1.58","vol":"2.88"},{"date":"2024-03-31","value":"1.79","vol":"3.08"},{"date":"2023-12-31","value":"1.86","vol":"3.01"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 速动比率 |
1.86 | 1.58 | 1.58 | 1.79 | 1.86 |
| 行业 | 2.59 | 2.91 | 2.88 | 3.08 | 3.01 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 9/228 ， 11/228。
[{"date":"2024-12-31","value":"39.05","vol":"31.03"},{"date":"2024-09-30","value":"40.04","vol":"33.03"},{"date":"2024-06-30","value":"42.89","vol":"33.21"},{"date":"2024-03-31","value":"38.71","vol":"33.13"},{"date":"2023-12-31","value":"41.04","vol":"33.46"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
39.05 | 40.04 | 42.89 | 38.71 | 41.04 |
| 行业(%) | 31.03 | 33.03 | 33.21 | 33.13 | 33.46 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"0.69","vol":"0.59"},{"date":"2024-09-30","value":"0.70","vol":"0.73"},{"date":"2024-06-30","value":"0.79","vol":"0.71"},{"date":"2024-03-31","value":"0.67","vol":"0.70"},{"date":"2023-12-31","value":"0.73","vol":"0.75"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.69 | 0.70 | 0.79 | 0.67 | 0.73 |
| 行业(%) | 0.59 | 0.73 | 0.71 | 0.70 | 0.75 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以买入为主，认为该股票非常值得关注。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 太平洋 | 2025-03-31 | 买入 | |
| 东吴证券 | 2025-03-30 | 买入 | |
| 国联民生 | 2025-03-29 | 增持 | |
| 开源证券 | 2025-03-28 | 买入 |
机构预测
机构预测该股2025年每股收益与前一年相同，长期投资价值一般。
[{"date":"2021","yellowRectValue":"17.76","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"19.09","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"19.54","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"20.61","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"22.84","blueLineValue":"2.48","type":"YC"}]